Hypoxia-inducible factor–prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease
Kidney International Supplements · 2021-04 · 11 (1) · 8-25
DOI: 10.1016/j.kisu.2020.12.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney International Supplements, 2021-04. Verfasst von Volker H Haase. Beteiligte Einrichtung: Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Die Arbeit wurde bisher 180-mal zitiert (Crossref) und nennt 160 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: BLRD VA, NIDDK NIH HHS, AstraZeneca.
Abstract (Originalsprache)
Hypoxia-inducible factor-prolyl hydroxylase domain inhibitors (HIF-PHIs) are a promising new class of orally administered drugs currently in late-stage global clinical development for the treatment of anemia of chronic kidney disease (CKD). HIF-PHIs activate the HIF oxygen-sensing pathway and are efficacious in correcting and maintaining hemoglobin levels in patients with non-dialysis- and dialysis-dependent CKD. In addition to promoting erythropoiesis through the increase in endogenous erythropoietin production, HIF-PHIs reduce hepcidin levels and modulate iron metabolism, providing increases in total iron binding capacity and transferrin levels, and potentially reducing the need for i.v. iron supplementation. Furthermore, HIF-activating drugs are predicted to have effects that extend beyond erythropoiesis. This review summarizes clinical data from current HIF-PHI trials in patients with anemia of CKD, discusses mechanisms of action and pharmacologic properties of HIF-PHIs, and deliberates over safety concerns and potential impact on anemia management in patients with CKD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden.
- Department of Molecular Physiology and Program in Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Förderung
- BLRD VA
- NIDDK NIH HHS
- AstraZeneca
- Vanderbilt University
Zitieren
APA
Haase, V. H. (2021). Hypoxia-inducible factor–prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease. Kidney International Supplements, 11(1), 8-25. https://doi.org/10.1016/j.kisu.2020.12.002
Vancouver
Haase VH. Hypoxia-inducible factor–prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease. Kidney International Supplements. 2021;11(1):8-25. doi:10.1016/j.kisu.2020.12.002
BibTeX
@article{Haase2021,
author = {Haase, Volker H},
title = {Hypoxia-inducible factor–prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease},
journal = {Kidney International Supplements},
year = {2021},
volume = {11},
number = {1},
pages = {8--25},
doi = {10.1016/j.kisu.2020.12.002}
}
EUVIMED